| First Author | Kerlin B | Year | 2004 |
| Journal | Blood | Volume | 103 |
| Issue | 5 | Pages | 1728-34 |
| PubMed ID | 14615369 | Mgi Jnum | J:129829 |
| Mgi Id | MGI:3770223 | Doi | 10.1182/blood-2003-08-2886 |
| Citation | Kerlin B, et al. (2004) Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood 103(5):1728-34 |
| abstractText | Elevated plasma levels of fibrinogen are associated with the presence of cardiovascular disease, but it is controversial whether elevated fibrinogen causally imparts an increased risk, and as such is a true modifier of cardiovascular disease, or is merely associated with disease. By investigating a transgenic mouse model of hyperfibrinogenemia, we show that elevated plasma fibrinogen concentration (1) elicits augmented fibrin deposition in specific organs, (2) interacts with an independent modifier of hemostatic activity to regulate fibrin turnover/deposition, (3) exacerbates neointimal hyperplasia in an experimental model of stasis-induced vascular remodeling, yet (4) may suppress thrombin generation in response to a procoagulant challenge. These findings provide direct experimental evidence that hyperfibrinogenemia is more than a by-product of cardiovascular disease and may function independently or interactively to modulate the severity and/or progression of vascular disease. |
